摘要
目的 :探讨膀胱移行细胞癌 (BTCC)中细胞粘附分子CD4 4V3与CD4 4V5表达的临床意义。方法 :采用免疫组织化学方法检测 86例BTCC患者及 10例正常膀胱粘膜组织中的CD4 4V3与CD4 4V5表达 ,并根据随访结果 ,采用双变量相关分析、COX多因素分析和Kaplan -Meier法进行生存分析。结果 :CD4 4V3、CD4 4V5在正常膀胱粘膜组织中不表达 ,其表达与BTCC的临床分期、病理分级呈负相关 ;CD4 4V3的高表达同CD4 4V5表达增强显著相关 ;CD4 4V3和CD4 4V5低表达是BTCC患者预后不良的独立危险因素 ;CD4 4V3和CD4 4V5同步表达患者比非同步表达或表达缺失患者有较低的术后复发率和较长的生存期。结论 :CD4 4V3、CD4 4V5在BTCC侵袭进程中发挥重要作用 ,可对其恶性程度及预后做出较准确的评估 ,对拟定全面的综合治疗方案有重要的指导意义。
Objective:To explore the clinical value of the expression of CD44V3 and CD44V5 in human bladder transitional cell carcinoma(BTCC). Methods:In 86 cases of BTCC which were followed up and 10 normal bladder tissues, the expression of CD44V3 and CD44V5 was analyzed by immunohistochemical techniques. The results were analyzed in a way of double variable quantity, COX regression and Kaplan-Meier methods.Results:The expression of CD44V3 and CD44V5 decreased with tumor grade and stage and disappeared in normal bladder epithelia. The expression of CD44V3 correlated significantly with increased expression of CD44V5.Low expression of CD44V3 and CD44V5 was independently associated with recurrence and poor prognosis. Patients maintained both CD44V3 and CD44V5 positive expression showed the lower recurrence and longer survival compared with patients with both negative expression. Conclusions: CD44V3 and CD44V5 play a key role in the invasive of BTCC. They can provide more accurate judgment of malignance and prognosis for BTCC. Then the results have a significant indication for working out clinical therapy scheme.
出处
《中国现代医学杂志》
CAS
CSCD
2003年第7期16-18,23,共4页
China Journal of Modern Medicine
